anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To develop formulations for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest.  &lt;P&gt;SOLUTION: Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. In the preferred embodiment, these formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a new axonal regenerating agent for central nervous system cells comprising β-cryptoxanthin having lower toxicity and a high activity at a lower concentration as an active ingredient.  &lt;P&gt;SOLUTION: The axonal regenerating agent for the central nervous system cells is characterized by comprising the β-cryptoxanthin as the active ingredient. An antidement agent is characterized by comprising the β-cryptoxanthin as the active ingredient and has inhibitory actions on apoptosis of the central nervous system cells. A functional food product is characterized in that a prescribed amount of the β-cryptoxanthin is formulated as the active ingredient to prepare the functional food product. Furthermore, the functional food product has the inhibitory actions on the apoptosis of the central nervous system cells. The β-cryptoxanthin has the excellent axonal regenerating actions on the nervous system cells, especially matured central nervous system cells. A drug comprising the compound as the active ingredient is useful as a therapeutic agent, or the like, for neurodegenerative diseases including the antidement agent.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide compounds that can be used for treating cell proliferative disorders (e.g., benign and malignant cancer cell-related disorders), and to provide pharmaceutical compositions containing the compounds.  &lt;P&gt;SOLUTION: There are provided the compositions and methods for inhibiting the cell cycle G2 checkpoint, in particular, the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides the compositions and methods for sensitizing cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. The compounds are used to treat proliferative disorders such as cancers. The invention provides the compositions and methods for selectively sensitizing G1 checkpoint-impaired cancer cells to DNA-damaging agents and treatments.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. It is clinically diagnosed by a resting mean pulmonary arterial pressure (mPAP) exceeding 20 mmHg . At present, PH\&amp;#39;s prevalence is approximated at 1 % of the global population and increases to 10 % for individuals over 65 years old, with considerable morbidity and mortality. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged a metabolic dysfunction and exert cardioprotective effects. DELIVER randomized trials have shown that ( dapagliflozin) can reduce all-cause mortality and hospitalizations due to HF in patients with HF with a mildly reduced or preserved LV function .

The beneficial effects of SGLT2i on the left ventricular systolic and diastolic function, and functional symptom burden have been demonstrated in several studies, but not much is known about the effects of these drugs on the right ventricular (RV) systolic function . The RV is often neglected because of its complex anatomy and the difficulty of obtaining satisfactory imaging "windows" in daily practice . However, the RV has been shown to play an important prognostic role following cardiac surgery and in patients with HF, pulmonary arterial hypertension, or ischemic heart disease . In clinical practice, the assessment of the RV function is usually undertaken by measuring only the longitudinal systolic function, as reflected in the measurement of the tricuspid annular plane systolic excursion (TAPSE) and tricuspid lateral annular systolic velocity (s' wave) derived from Doppler tissue imaging. The fractional area change (FAC), on the other hand, gives us an insight into the radial contraction of the RV \[8\]. Because these parameters are load- and angle-dependent, advanced echocardiographic methods, such as speckle-tracking echocardiography (STE) measuring the longitudinal strain of the RV free wall (RV FWS) , have recently emerged as more accurate estimates of the RV systolic function . TAPSE and s' wave measure only the longitudinal RV function in the basal region of the RV free wall and were shown to be an independent predictor of cardiac death and major adverse cardiovascular events (MACE) in patients with diverse cardiovascular diseases. Furthermore, the ratio between the TAPSE and systolic pulmonary artery pressure (SPAP) represents the non-invasive measurement of the right ventriculo-arterial coupling and the RV contractile function.

For these reasons, Investigators designed the present study to investigate the effects of SGLT2 espacially dapagliflozin on the RV systolic function after it was added to optimal medical therapy (OMT) on the patient with pulmonary hypertension
A method for detecting an HBV-derived nucleic acid target sequence in a sample comprises subjecting the sample to denaturing conditions to yield single stranded forms of the target sequence then contacting the sample with a set of primer which comprises at least two primers selected from: SEQ ID NO:1 ( caaggtatgttgcccgtttgt ) and SEQ ID NO:2 ( tggctcagtttactagtgccatt ), primers complementary to SEQ ID NO:1 and 2 and primers having at least 70% similarity thereto. The primers hybridize to regions corresponding to or flanking a conserved nucleotide sequence within or part of the nucleotide sequence encoding HbsAG, wherein at least one primer is capable of hybridizing to one strand of the target sequence and the other primer is capable of hybridizing to a strand complementary and wherein the primers are extendable from their 3&#39; termini to form an extension product complementary to the strand to which each of the primers has hybridized. The sample is then subjected to conditions to facilitate amplification and then detecting for the presence of the amplification product wherein the presence of the amplified product indicates HBV-derived nucleic acid target sequence. One of the primers may be immobilized to a solid support with the other primer in a solution phase. Also described is an array of two or more oligonucleotide primers immobilized to a solid support . (62) Divided out of 511883
A topical sanitizing composition for restoring skin&#39;s natural balance of bacteria is provided. The topical sanitizing composition includes about 0.02 wt. % to 10.0 wt. % of an active ingredient, at least about 40 wt. % of one or more C1-6 alcohols; and water. The active ingredient comprises one or more of a probiotic, probiotic derivative, and a prebiotic.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an α-keto acid reductase and a method for producing an optically active α-hydroxy acid utilizing the enzyme.  &lt;P&gt;SOLUTION: The α-keto acid reductase is derived from Leuconostoc mesenteroides subsp. dextranicum. A DNA encoding the α-keto acid reductase is isolated. The enzyme and its homolog reduce an α-keto acid in the presence of NADH to produce the optically active α-hydroxy acid. The α-hydroxy acid includes an optically active mandelic acid derivative (formula II). The obtained optically active mandelic acid derivative is useful as an intermediate for synthesizing medicines or agrochemicals.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PROBLEM TO BE SOLVED: To obtain non-human animals having the spinal disorder which is very short in aortic block time, is minimized in factors exclusive of glutamic acid, etc., and is adequate for evaluation of medicinal effects by making the spinal cord ischemic under specific conditions and locally administering the glutamic acid, etc., thereto. SOLUTION: The aorta is blocked at &gt;=2 points to form the segments of the aorta so as to include the parts where the nutrition blood vessels communicating with the spinal cord are branched between these blocking points, by which the spinal cord is made ischemic. In addition, the glutamic acid or aspartic acid (the soln. concn. is preferably &gt;=20mM) is locally administered to these segments, by which the non-human animals, such as rabbits, rats, cats, dogs, pigs and monkeys, having the spinal disorder are obtd. The evaluation of the spinal disorder treating medicine derived from the glutamic acid or aspartic acid is preferably executed by using such animals.
FIELD: biotechnology. SUBSTANCE: invention relates to new compounds named as &#34;leistroduxins&#34; with the corresponding structural formula. Leistroduxins and their salts can be obtained by fermentation of microorganisms of genus Streptomyces, in part, Streptomyces platensis, strain FEPM BP-3288. Leistroduxins can be used for treatment and prophylaxis of unfavorable responses as result of chemotherapy or radiotherapy of cancer, infections, cerebral disorders and fungal infections. EFFECT: enhanced effectiveness of agent. 8 cl, 1 tbl
NEW MATERIAL:A compound of formula I [R&lt;1&gt; is Ac (acetyl) or H; R&lt;2&gt; is Bn (benzyl) or Ac; R&lt;3&gt; is NPhth (Phth is phthaloyl) or NHAc; R4 is Ac, Bn, etc.; Me is methanol]. USE:Useful for clarification of biochemical behavior of sugar chains of relation to cancer. PREPARATION:A compound of formula II is initially reacted with a compound of formula III and the resultant product is treated with hydrazine to remove a phthaloyl group followed by acetylation, debenzylation and acetylation in order. The obtained product is subsequently hemiacetalized and then treated with a halogenated acetonitrile for imidation. The resultant imidated compound is finally reacted with a ceramid compound of formula IV, thus obtaining the exemplified compound.
The cosmetic preparation is used as a mask. It has simultaneously deep cleaning, feeding and tonic effect, smoothens and refreshes the skin, and can be used only in the zones of wrinkle formation. The preparation forms a food film which can be removed in dry, after which the face has only to be washed with cool water and there is no need of any application of feeding and protection cream. There are no unwanted side effects and causes no allergic reactions. Clear antiphlogistic and therapeutic effect is attained on any manifestations of Acne vulgaris. The cosmetic preparation is a dry lactic product, containing, in wt.%: low lactose wholesome or skimmed cows&#39; milk from 48 to 70, low lactose skimmed milk hydrolysate of over 95% degraded lactic casein containing oligo-, di- and tri-peptides and free amino acids from 8 to 20; low lactose wholesome or skimmed milk, fermented with selected strains of Lactobacillus delbrueckii subsp. bulgaricus, containing up to 950 mln/g live and latent cells and to 160 mg. % free amino acids from 4.0 to 8.5, pectine about 1, saccharose from 11 to 18 and optionally low lactose and galactose-free protein precipitate from 0 to 15. The means contains no preservatives. 1 claim
Surfactant combinations which need to have an increased viscosity on the grounds of their applications have disadvantages with regard to the tolerability by skin and the mucous membranes of the eye. Mild surfactants such as alkyl oligoglycosides or carboxymethylated ethoxylates cannot, however, be sufficiently thickened, for example with electrolyte. …&lt;??&gt;The surfactant combination is intended not to have these disadvantages. …&lt;??&gt;Therefore an aqueous combination of alkyl oligoglycosides, carboxymethylated ethoxylates, electrolyte and additives which has a synergistic thickening effect is proposed. …&lt;??&gt;Aqueous combinations of alkyl oligoglycoside, carboxymethylated ethoxylates, electrolyte and additives are used as a basis for shampoos, bath and shower gels and other cosmetic formulations with increased viscosity.
NEW MATERIAL:2-N-{3-[3-( 1-Piperidinomethyl )phenoxy]propyl}amino-5-amino- 1,3,4-thiadiazole. USE:It has excellent antagonistic activity to histamine H2 receptor, and is useful as an agent for suppressing the secretion of the gastric acid and as an antiulcer agent. it has long-acting activity and no side effect, and can be administered orally or parenterally. PREPARATION:The compound of formula I can be produced by the cyclization reaction of the compound of formula II. The reaction is carried out in an organic solvent such as benzene, toluene, etc. in the presence of a condensation agent such as N,N&#39;-dicyclohexyl-carbodiimide, diethyl azodicarboxylate, and triphenyl phosphine, etc. at room temperature or under refluxing. The amount of the condensation agent is usually 1-3mol of N,N&#39;-dicyclohexyl carbodiimide per 1mol of the compound of formula II.
The invention discloses a high-stereo and highly-enantioselective oxazolinedione compound, a preparation method and an application thereof. The structural formula of the compound is as shown in the specification, wherein Ar=Ph, m-ClPh, m-MePh and m-MeOPh. The high-stereo and highly-enantioselective oxazolinedione compound is synthesized by a new method. The high-stereo and highly-enantioselective oxazolinedione compound has different degrees of characteristics of inhibiting H22 hepatocarcinoma cell activity. At present, the method hasn&#39;t been reported. The new method has the following advantages: the method can be adopted universally; cost is low; reaction path is short; postprocessing is simple; and by highly efficient preparation of the compound, a highly diastereoselective compound with high optical purity is obtained.
Disclosed herein are cold slurry formulations, devices, and methods for alleviating symptoms of ocular surface discomfort. Cold slurry formulations comprising ice, a freezing temperature depressant, and, optionally, a. lipid are disclosed. Devices and methods for protecting a target ocular surface from contacting a cold slurry formulation that is used to maintain the target ocular surface at a temperature desired for alleviating symptoms of ocular surface discomfort are disclosed. Self-contained devices configured to receive a cold, slurry&#39; formulation for maintaining the target ocular surface at a temperature desired for alleviating symptoms of ocular surface discomfort are disclosed. Devices and methods are disclosed, for protecting a cornea, and/or eyelid of a subject from the freezing cold slurry formulation that is directly or indirectly applied or injected into the target ocular surface. Kits comprising multiple syringes for administering multiple doses of the cold slurry to the target ocular surface, are disclosed.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a film preparation rapidly soluble in the oral cavity by combining phenylephrine hydrochloride with hydroxypropyl cellulose and/or hydroxypropyl methylcellulose.  &lt;P&gt;SOLUTION: The rapidly soluble film preparation 1 containing phenylephrine hydrochloride has a resin film 3, one or more shielding layers 5 and one or more drug-containing layers 7. The shielding layer 5 is formed on the resin film 3, contains an edible polymer material and is free from phenylephrine hydrochloride. The drug-containing layer 7 is formed on the shielding layer 5 and contains phenylephrine hydrochloride and at least one kind of substance selected from hydroxypropyl cellulose and hydroxypropyl methylcellulose. The rapidly soluble film preparation 1 containing phenylephrine hydrochloride may optionally have one or more shielding layers 5 containing an edible polymer material and free from phenylephrine hydrochloride on the drug-containing layer 7.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
1. Technical Result Increase in efficiency of treatment of Alzheimer&#39;s disease. 2. Essence The present invention provides a method of treating Alzheimer&#39;s disease using a novel compound of formula (I), wherein X, Y and P have the values indicated in the description. Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of formula (I) and a method of imaging amyloid deposits using isoindoline derivatives. 3. Field of Application Medicine.
A method and a process are disclosed for preparation of medical electro-powders. The electro-powder results from preparations of chemical and biological substances to form electro-powders suitable for electrostatic charging and dosing for functionality in a dry powder inhaler device. The electro-powder resulting from the method and process forms an active powder substance or a dry powder medical formulation with a fine particle fraction representing of the order 50 % or more of the content having a size ranging between 0,5-5 νm and provides electrostatic properties with an absolute specific charge per mass after charging of the order 0.1x10-6 to 25x10-6 C/g and presenting a charge decay rate constant Q¿50? &gt; 0.1 sec with a tap density of less than 0.9 g/ml and a water activity aw of less than O.5. In the processing the active substance is a generally pharmacologically active chemical or biological substance, for instance a polypeptide or any other corresponding substance selected alone or mixed or blended together with one or more excipients being a compound to improve electrostatic properties of the medical dry powder substance or dry powder medical formulation. Further the electro-powder may even be formed as a micro-encapsulation by coating micronized powder with the excipient in such a way that the active substance is capsulated whereby the powder electrostatic properties mainly comes from the excipient.
Systems and methods to assist an emergency medical dispatcher in responding to emergency calls are disclosed. A computer-implemented emergency dispatch protocol is provided that includes interrogatories for a dispatcher to ask a caller to generate an appropriate response. A diagnostic tool is provided to aid a dispatcher in determining a likelihood that the patient has meningitis. The diagnostic tool determines a likelihood that the patient has meningitis based on caller-relayed information concerning the caller&#39;s observations of the patient. The diagnostic tool can be launched automatically by the emergency dispatch protocol, or manually, as desired by a dispatcher. The diagnostic tool presents a user interface that may provide, among other things, questions to guide the caller in identifying signs and symptoms that the patient has meningitis and input components associated with the questions.
672,814. Moulding by dipping. PARKE, DAVIS &amp; CO. Nov. 25, 1949, No. 30277/49. Class 87(ii) In the method of making hard-shell medicinal capsules which comprises dipping a mould pin in a solution of capsule-forming material and withdrawing the pin with an adherent coating of the material, the coated pin is subjected to cooling air directed through a hood in order to set the composition before the coated .pin is allowed to remain stationary for any substantial length of time. The invention is described as an addition to the capsule making machine described in Specification 360,427 in which mould pins P arranged in rows on strips G are assembled in groups of five strips and dipped in a tank of the heated capsule-forming composition (not shown). The set of strips is then raised on a rotating elevator E&#39; and displaced laterally on to a table K, with the pins upward. When four groups of five strips each G&lt;SP&gt;1&lt;/SP&gt;-G&lt;SP&gt;4&lt;/SP&gt; are on the table they are moved to the right into the second position P&lt;SP&gt;2&lt;/SP&gt; and a new set of four groups is assembled in the first position P&#39; and so on, the groups being intermittently advanced to the right towards a drying stage (not shown). The rotation of the elevator E&lt;SP&gt;1&lt;/SP&gt; prevents the coating on the mould pins from running until they are placed on the table K. The pins are then subjected to a stream of cool air (less than 65‹F.) from a hood H fed from a pipe M. Each pin receives a jet of air from a hole H&lt;SP&gt;2&lt;/SP&gt; in a plate covered by a filter web H&lt;SP&gt;3&lt;/SP&gt;. This sets the coating quickly and enables the machine to be used for materials which take longer to set than ordinary gelatin, such as for example the composition described in Specification 638,284, or cellulose acetate phthalate, polyvinyl alcohol, cellulose acetate, or ethyl cellulose.
NEW MATERIAL:The peptide of formula I (A is Ser or Tyr; B is Gly or Glu; X is Ala or Val; the steric configuration of amino acid residues is D, L or DL). EXAMPLE:H-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Ser-Gly-Glu-Leu-Phe-Asp-Ala-OH. USE:A synthetic intermediate of the peptide of formula II[Y is OH or NR&lt;1&gt;R&lt;2&gt; (R&lt;1&gt; and R&lt;2&gt; are H or alkyl)] having analgesic activity. Useful for the preparation of an antiserum acting specifically to the peptide of formula II, and for the detection and determination of prodynorphin. PROCESS:After protecting the amino groups and carboxyl groups having no participation in the reaction, the required peptide chains are bonded successively to the C-terminal according to the peptide synthesis process. The protecting groups are removed from the obtained ptotected peptide by conventional method to obtain the objective peptide of formula I .
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapeutic treatment method for maintaining neural pathways in a mammal cell; and to provide a composition and a device.  &lt;P&gt;SOLUTION: The therapeutic treatment method for maintaining the neural pathways includes enhancing survival of neurons at risk of dying, inducing cellular repair of neurons and the neural pathways, and maintaining their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in the neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The method, device and composition include a morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To obtain the titled cosmetic with improved releasability and operability without slip in joined surface, by using a mold consisting of a silicone rubber and silicone resin. CONSTITUTION:A lipstick stock solution 1 is injected into cavity holes 2 formed from a mold 3 consisting of a silicone rubber and/or silicone resin and/or silicon resin coating material and mold pieces 1. After solidifying the stock solution (a), the mold 3 is removed from the mold pieces 1. A mold piece 1&#39; is then joined to the mold piece 1 so as to aligne the cavity holes 2 and 2&#39;. A lipstick stock solution (b) of a different color is then injected into the cavity hole 2&#39;. After solidifying the above-mentioned stock solution (b), the mold pieces 1 and 1&#39; are removed. The joined interface of both bases becomes structurally storing after completion without breaking the textural structure of the cosmetic base interface in a process of removing the mold 3.